Genmab — Januar 2026
-
Europæiske life science-aktier tager teten efter afvist sparemanøvre fra Trump https://proinvestor.com/investornyt/1400080/europaeiske-life-science-aktier-tager-teten-efter-afvist-sparemanovre-fra-trump
-
Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI
▼ (teclistamab) in combination with DARZALEX (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-the-european-medicines-agency-for-tecvayli-teclistamab-in-combination-with-darzalex-daratumumab-subcutaneous-formulation-for-patients-with-relapsed-refractory-multiple-myeloma -
genmab was still adding hospitals to the ABBIL1TY NSCLC trial just last month... probably testament to how sudden the decision was to stop acasunlimab development
... https://clinicaltrials.gov/study/NCT06635824?tab=history&a=14&b=15#version-content-panel -
Genmab har også noget at indhente, hvis kurstendensen fra sidste år skal gentages i år
-
20 min til luk og kursen er nu steget over 5%
-
Lad os se i morgen, hvor mange som skummer
-
Tvunget til at sælge?? Det må, efter min opfattelse, være en situation, hvor man tidligere har handlet lidt overilet ??
-
Det kan du have ret i, @nohope. Men, den slags, har man - som regel - nogen tid til af forberede
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind